Clinical pharmacology and malaria.
The role of clinical pharmacology in improving the prevention and treatment of malaria is reviewed. A series of general and specific issues is discussed, concentrating on risk-benefit and cost-effectiveness. The techniques of clinical pharmacokinetics play an important role in the optimal use of drugs and this is illustrated by studies on quinine and proguanil. In discussing amodiaquine toxicity, the role of the pharmacologist and the chemist in designing out drug toxicity lends hope for producing a new generation of antimalarial drugs.
Breckenridge
A M
AM
Department of Pharmacology and Therapeutics, University of Liverpool, U.K. a.m.breckenridge@liv.ac.uk
Winstanley
P A
PA
D000655:Amodiaquine / Q000009:adverse effects; D000962:Antimalarials / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D002727:Proguanil / Q000031:analogs & derivatives / Q000627:therapeutic use; D011803:Quinine / Q000494:pharmacology / Q000627:therapeutic use; D018570:Risk Assessment
D000962:Antimalarials; D000655:Amodiaquine; C007030:chlorproguanil; D011803:Quinine; D002727:Proguanil